Adjuvant systemic therapy of breast cancer

Breast Care

Volumn 6, Issue 3, 2011, Pages 179-183

  Schuetz, Florian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Endocrine therapy

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURGERY; CELL PROLIFERATION; DISEASE FREE SURVIVAL; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOLOGY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMIC THERAPY; TUMOR CELL;

EID: 79959908873     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000329336     Document Type: Review

References (32)

1. Early Breast Cancer Trialists' Collobarative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
2. Jahanzeb M: Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008;8:324-333.
3. www.nccn.org/professionals/physician-gls/f-guide-lines.asp.
4. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; panel members: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-1329.
5. www.ago-online.org.
6. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N: uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008;45:31-45.
7. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S: The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 2011;126:797-802.
8. Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F, Glas AM: Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights 2010;28:129-138.
9. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-920. (Pubitemid 32624648)
10. Yagata H, Kajiura Y, Yamauchi H: Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011, in press.
11. Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Bono P, Lindman H; Fin XX study investigators: Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. www.abstracts2view. com/sabcs10/view.php?nu= SABCS10L-564.
12. O'Shaughnessy J, Paul D, Stokoe C, Pippen J Jr, Blum JL, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Pluenneke R, Schwartz J, Jones S, Brownstein C, Gilberg F: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. www.abstracts2view.com/sabcs10/view.php?nu= SABCS10L-954.
13. Bedard PL, Di Leo A, Piccart-Gebhart MJ: Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010;7:22-36.
14. Martin M, Iluch A, Segui A, Ruiz A, Ramos A, Adrover Cebrián E, Rodriguez-Lescure A, Grosse R, Calvo Martínez L, Anton A: Multi-center, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing TAC with FAC: 5-year efficacy analysis of the GEICAM 9805 trial. J Clin Oncol 2008;26(suppl):abstr 542.
15. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671. (Pubitemid 351549913)
16. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-1183.
17. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE: Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009;27:2938-2945.
18. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671. (Pubitemid 351549913)
19. Burnell M, Levine M, Chapman JA, Bramwell V, Gelmon K, Walley B, Whelan T, Albain K, Perez E, Rugo H, Ding Z, O'Brien P, Shepherd L, Pritchard K: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. San Antonio Breast Cancer Symposium, 2006.
20. Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, Cohen AF, Burggraaf J: Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol 2008;134:961-968.
21. Swain SM, Arezzo JC: Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455-467.
22. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of pre-operative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493. (Pubitemid 27289876)
23. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized Gepar Trio study. J Natl Cancer Inst 2008;100:552-562.
24. Al Saleh S, Sharaf LH, Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 2011;38:1197-1217.
25. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-1955.
26. Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M, Brauch H: CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-4477.
27. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S: CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011;103:489-500.
28. Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist LE, Fornander T: Interaction between goserelin and tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. www.abstracts-2view.com/sabcs10/view.php?nu=SABCS10L-981.
29. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-518.
30. Viale G, Regan MM, Dell'orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, Macgrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS; for the BIG 1-98 Collaborative and International Breast Cancer Study Groups: Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011, in press.
31. Gray RG, Rea DW, Handley K, Marshall A, Pritchard MG, Perry P, Earl HM, Poole CJ, Salman A, Lee M, aTTom Collaborators, aTTom (adjuvant Tamoxifen-To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-preliminary results. J Clin Oncol 2008;26(suppl):abstr 513.
32. Goss P, Ingle J, Martino S, Robert N, Muss H, Shepherd L, Pritchard K, Livingston R, Davidson N, Perez E, Cameron D, Whelan T, Palmer M, Tu D: Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. Cancer Res 2009;69(suppl):abstr 13.